VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

Group 1 - VYNE Therapeutics Inc. reported a quarterly loss of $0.29 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.24, representing an earnings surprise of -20.83% [1] - The company posted revenues of $0.12 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 10%, and showing a slight increase from $0.11 million in the same quarter last year [2] - VYNE Therapeutics shares have increased approximately 34.3% since the beginning of the year, outperforming the S&P 500's gain of 24.3% [3] Group 2 - The earnings outlook for VYNE Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.26 on revenues of $0.2 million, and for the current fiscal year at -$0.86 on revenues of $0.6 million [7] - The Medical - Drugs industry, to which VYNE Therapeutics belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]